Tags

Type your tag names separated by a space and hit enter

Current status of ex-vivo liver resection and autologous liver transplantation for end-stage hepatic alveolar echinococcosis.
Ann Palliat Med. 2020 Jun 12 [Online ahead of print]AP

Abstract

Hepatic alveolar echinococcosis (HAE) is a cosmopolitan zoonosis distribute widely in the northern hemisphere with high estimated 10-year mortality. Radical resection combined with oral albendazole administration are the major methods for HAE treatment, whereas most patients delayed diagnosis and treatment because which was considered as benign disease. For the cases with end-stage HAE could not be treated through conventional hepatectomy, allograft liver transplantation (LT) was regarded as a life-saving technique previously. However, graft shortage, high recurrence rate and long-term immunosuppressive therapy limited its utilization. Since the ex-vivo liver resection and autotransplantation (ERAT) procedure was first used in treating for end-stage HAE in 2011, there are more than 120 HAE cases patients were reported treating in this method up to now. Comparing with LT, ERAT needs neither an organ donor nor long term immunosuppressive therapy, and provide preferable overall survival rates. Based on the conventional ERAT procedure, some modification such as auxiliary partial autologous LT were introduced in the high selected end-stage HAE patients presently. However, the standard procedures for ERAT including surgical details and perioperative management have not been established because of limited reported cases. Also, the present ERAT experience for end-stage HAE treatment are all summarizes by the Chinese surgeon groups. For summarizing the knowledge and experience details, we reviewed present opinions about ERAT for end-stage HAE patients, and presented the future perspectives about this topic in this manuscript. We aimed at discussing the feasibility, indications, preparation, technical details, and postoperative outcomes of ERAT for HAE patients.

Authors+Show Affiliations

Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province & Organ Transplantation Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province & Organ Transplantation Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province & Organ Transplantation Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province & Organ Transplantation Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. 68532815@qq.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32576011

Citation

Yang, Chong, et al. "Current Status of Ex-vivo Liver Resection and Autologous Liver Transplantation for End-stage Hepatic Alveolar Echinococcosis." Annals of Palliative Medicine, 2020.
Yang C, Yang HJ, Deng SP, et al. Current status of ex-vivo liver resection and autologous liver transplantation for end-stage hepatic alveolar echinococcosis. Ann Palliat Med. 2020.
Yang, C., Yang, H. J., Deng, S. P., & Zhang, Y. (2020). Current status of ex-vivo liver resection and autologous liver transplantation for end-stage hepatic alveolar echinococcosis. Annals of Palliative Medicine. https://doi.org/10.21037/apm-20-184
Yang C, et al. Current Status of Ex-vivo Liver Resection and Autologous Liver Transplantation for End-stage Hepatic Alveolar Echinococcosis. Ann Palliat Med. 2020 Jun 12; PubMed PMID: 32576011.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current status of ex-vivo liver resection and autologous liver transplantation for end-stage hepatic alveolar echinococcosis. AU - Yang,Chong, AU - Yang,Hong-Ji, AU - Deng,Shao-Ping, AU - Zhang,Yu, Y1 - 2020/06/12/ PY - 2020/6/25/entrez KW - Ex-vivo liver resection and autotransplantation (ERAT) KW - hepatic alveolar echinococcosis (HAE) KW - liver transplantation (LT) KW - vascular reconstruction JF - Annals of palliative medicine JO - Ann Palliat Med N2 - Hepatic alveolar echinococcosis (HAE) is a cosmopolitan zoonosis distribute widely in the northern hemisphere with high estimated 10-year mortality. Radical resection combined with oral albendazole administration are the major methods for HAE treatment, whereas most patients delayed diagnosis and treatment because which was considered as benign disease. For the cases with end-stage HAE could not be treated through conventional hepatectomy, allograft liver transplantation (LT) was regarded as a life-saving technique previously. However, graft shortage, high recurrence rate and long-term immunosuppressive therapy limited its utilization. Since the ex-vivo liver resection and autotransplantation (ERAT) procedure was first used in treating for end-stage HAE in 2011, there are more than 120 HAE cases patients were reported treating in this method up to now. Comparing with LT, ERAT needs neither an organ donor nor long term immunosuppressive therapy, and provide preferable overall survival rates. Based on the conventional ERAT procedure, some modification such as auxiliary partial autologous LT were introduced in the high selected end-stage HAE patients presently. However, the standard procedures for ERAT including surgical details and perioperative management have not been established because of limited reported cases. Also, the present ERAT experience for end-stage HAE treatment are all summarizes by the Chinese surgeon groups. For summarizing the knowledge and experience details, we reviewed present opinions about ERAT for end-stage HAE patients, and presented the future perspectives about this topic in this manuscript. We aimed at discussing the feasibility, indications, preparation, technical details, and postoperative outcomes of ERAT for HAE patients. SN - 2224-5839 UR - https://www.unboundmedicine.com/medline/citation/32576011/Current_status_of_ex-vivo_liver_resection_and_autologous_liver_transplantation_for_end-stage_hepatic_alveolar_echinococcosis L2 - https://doi.org/10.21037/apm-20-184 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.